Future trends in the treatment of rosacea

Cutis

Volumn 75, Issue 3 SUPPL., 2005, Pages 33-36

  Bikowski, Joseph B ^{a,g,h,i,j,k,l,m,n,o,p,q,r,s}   Del Rosso, James Q ^{a,b,j,l,o,q,s,t,u}   Goldberg, David J ^c   Margolis, David J ^d   Van Zuuren, Esther J ^e   Wolf Jr , John E ^a,f,l,o  

^a School of Medicine ^*

^b UNIVERSITY OF NEVADA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g 3M COMPANY   (United States)

^h ALLERGAN INC   (United States)

ⁱ Aventis

^j Berlex Laboratories   (United States)

^k BIOGEN   (United States)

^l Managed Care and Professional Affairs   (United States)

^m Dermik Laboratories   (United States)

ⁿ ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^o Galderma Laboratories   (United States)

^p GLAXOSMITHKLINE   (United Kingdom)

^q Healthpoint Ltd   (United States)

^r Text Mining Services   (Switzerland)

^s Stiefel Laboratories Inc   (United States)

^t Bradley Pharmaceuticals Inc   (United States)

^u UNILEVER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZELAIC ACID; AZITHROMYCIN; DICLOFENAC; DOXYCYCLINE; METRONIDAZOLE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PERMETHRIN; PIMECROLIMUS; SULFACETAMIDE; SULFUR; TSUKUBAENOLIDE;

CONFERENCE PAPER; DISEASE EXACERBATION; HUMAN; PIGMENT DISORDER; ROSACEA; SEBORRHEIC DERMATITIS; SKIN IRRITATION; TREATMENT OUTCOME;

EID: 17144376037     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Gollnick H, Cunliffe W, and the Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dematol. 2003;49(suppl 1):S1-S37.
2. Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed. 2003;2:43-47.
3. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-587.
4. Wilkin J, Dahl M, Detmar M, et al, for the National Rosacea Society Expert Committee. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2004;50:907-912.
5. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003;2:234-245.
6. Dahl MV, Ross AJ, Schlievert PM. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol. 2004;50:266-272.
7. Powell FC. What's going on in rosacea? J Eur Acad Derm Venereol. 2000;14:351-352.
8. Preshaw PM, Hefti AF, Jepsen S, et al. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. J Clin Periodontol. 2004;31:697-707.
9. Orenstein A, Haik J, Tamir J, et al. Treatment of rhinophyma with Er:YAG laser. Lasers Surg Med. 2001;29:230-235.
10. Taub AF. Photodynamic therapy in dermatology: history and horizons. J Drugs Dermatol. 2003;3(suppl 1):S8-S25.
11. Mark KA, Sparacio RM, Voigt A, et al. Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Dermatol Surg. 2003;29:600-604.
12. Clark SM, Lanigan SW, Marks R. Laser treatment of erythema and telangiectasia associated with rosacea. Lasers Med Sci. 2002;17:26-33.
13. Angermeier MC. Treatment of facial vascular lesions with intense pulsed light. J Cutan Laser Ther. 1999;1:95-100.
14. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-1450.
15. Draelos ZD. Clinical situations conducive to proactive barrier enhancement. Cutis. 2002;70(suppl 6):17-20, 21-23.